Literature DB >> 8759905

Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods.

Z Rudzki1, E M Duncan, G J Casey, M Neumann, E J Favaloro, J V Lloyd.   

Abstract

A subgroup of patients with haemophilia A who have a familial discrepancy between the one-stage and two-stage factor VIII:C results has previously been described. These patients show factor VIII:C levels by one-stage assay that are 2-7-fold higher than their two-stage results. We have studied 10 such families and identified six different mutations in the factor VIII gene in this group. The chemical cleavage method and DNA sequencing was used to identify mutations in factor VIII gene fragments generated by reverse transcription and PCR. All available family members were tested to confirm the presence of the mutation in affected individuals. These patients were found to have one of six single point substitutions causing a missense mutation and alteration to one codon in exons 7, 11, 14 or 18. The mutations comprise three that have not previously been described (Ala284Glu. Arg698Leu. Leu1932Phe) and three that have been previously described (Ser289Leu, Arg531His, Arg698Trp). Alterations to the amino acid composition of the A1, A2 and A3 domains of factor VIII are predicted by these molecular studies. In contrast, a control group of 23 mild haemophilia families with equivalent factor VIII:C results by one-stage and two-stage assays did not have any of the above mutations. Detailed studies in seven of these latter families identified four mutations affecting the A3, C1 and C2 domains of factor VIII. These findings suggest a genetic basis to the unusual factor VIII phenotype but do not explain the mechanism of the discrepant factor VIII activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759905     DOI: 10.1046/j.1365-2141.1996.d01-1792.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

2.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

3.  Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A.

Authors:  Hiroshi Inaba; Keiko Shinozawa; Ikuo Seita; Manabu Otaki; Takashi Suzuki; Takeshi Hagiwara; Kagehiro Amano; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2013-04-27       Impact factor: 2.490

4.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 5.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

6.  Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

Authors:  M Monaghan; H Wakabayashi; A Griffiths; J Wintermute; P J Fay
Journal:  Thromb Haemost       Date:  2014-06-05       Impact factor: 5.249

7.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

8.  Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Authors:  Hironao Wakabayashi; Fatbardha Varfaj; Jennifer Deangelis; Philip J Fay
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

9.  Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2008-12-04       Impact factor: 5.824

10.  Activated protein C has a regulatory role in factor VIII function.

Authors:  Amelia R Wilhelm; Nicole A Parsons; Benjamin J Samelson-Jones; Robert J Davidson; Charles T Esmon; Rodney M Camire; Lindsey A George
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.